Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 6:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 285 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Insulin, Regular, Human Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

The Role of Cholinergic Signaling for Mediating the Effects of GIP and/or Xenin-25 on Insulin Secretion

NCT01951729
View directory record Official record
Conditions
Pre-diabetes
Interventions
Control, Xenin-25 without atropine, GIP without atropine, Placebo with atropine, Xenin-25 with atropine, GIP with atropine, GIP plus Xenin-25 without atropine, GIP plus Xenin-25 with atropine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 25, 2018 · Synced Oct 11, 2026, 6:59 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Feasibility Study of PID Versus MPC and HMS

NCT01987206
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
MPC control algorithm, PID control algorithm
Device
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2016 · Synced Oct 11, 2026, 6:59 PM EDT
Not listed Phase 3 Interventional

Active Comparator Study of Generex Oral-lyn™ Spray and Injected Human Insulin

NCT00668850
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Generex Oral-lyn™, Regular human insulin
Drug
Lead sponsor
Generex Biotechnology Corp.
Industry
Eligibility
18 Years to 75 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
8
States / cities
2001 Santa Monica Blvd Suite 390W, California • 1150 N. 35th Ave Suite 590, Florida • 7400 North Shadeland Ave, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 11, 2026, 6:59 PM EDT
Completed Phase 3 Interventional

Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children

NCT00102817
View directory record Official record
Conditions
Growth Hormone Disorder, Pituitary Dwarfism
Interventions
somatropin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
3 Years to 13 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
27
States / cities
Los Angeles, California • San Diego, California • Stanford, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 11, 2026, 6:59 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Neural Mechanism of Aldosterone-induced Insulin Resistance

NCT02102243
View directory record Official record
Conditions
Hypertension
Interventions
DEFINITY® infusion, Human Recombinant Regular Insulin infusion, Dextrose infusion, Flow mediated vasodilation, Endothelial cell collection, Microvascular perfusion assessment using Definity, Microneurography
Drug · Procedure
Lead sponsor
Wanpen Vongpatanasin
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 11, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Rett Syndrome With Recombinant Human IGF-1

NCT01777542
View directory record Official record
Conditions
Rett Syndrome
Interventions
Recombinant Human Insulin Growth Factor 1 (rhIGF-1), Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 10 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2018 · Synced Oct 11, 2026, 6:59 PM EDT
Completed Phase 3 Interventional

Compare Two Dosing Algorithms in Insulin-Naive Patients With Type 2 Diabetes Mellitus

NCT00391209
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder, intensive diabetes management starting with an adjusted dose of Human Insulin Inhalation Powder
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
17
States / cities
Santa Ana, California • Washington D.C., District of Columbia • Hollywood, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 11, 2026, 6:59 PM EDT
Completed Phase 2 Interventional

Comparator Trial Using Insulin Glulisine vs. Insulin Lispro for Treatment of Gestational Diabetes

NCT01662921
View directory record Official record
Conditions
Diabetes During Pregnancy
Interventions
NPH, Insulin LISPRO, Insulin glulisine
Drug
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 11, 2026, 6:59 PM EDT
Completed Phase 2 Interventional

Comparing Intensive and Standard Training for Human Insulin Inhalation Powder (HIIP)

NCT00099515
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY041001 (HIIP)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
3
States / cities
Clearwater, Florida • Buffalo, New York • New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2007 · Synced Oct 11, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Results available

Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease

NCT01868997
View directory record Official record
Conditions
Thyroid Associated Ophthalmopathies, Thyroid-Associated Ophthalmopathy
Interventions
teprotumumab, normal saline
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
11
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Oct 11, 2026, 6:59 PM EDT
Active, not recruiting Phase 2 Interventional

Islet Cell Transplant for Type 1 Diabetes

NCT01909245
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Allogenic Human Islet Cells, Immunosuppressive Agents, Gastrin 17
Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 68 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 11, 2026, 6:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study in Healthy Volunteers

NCT01365117
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Technosphere® Insulin Inhalation Powder
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Oct 11, 2026, 6:59 PM EDT
Completed Phase 1 Interventional

VRS-317 in Adult Subjects With Growth Hormone Deficiency

NCT01359488
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
VRS-317
Drug
Lead sponsor
Versartis Inc.
Industry
Eligibility
25 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2012 · Synced Oct 11, 2026, 6:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

COMIDAS Comparing Original Mexican Diets and Standard US Diets

NCT01369173
View directory record Official record
Conditions
Healthy
Interventions
Mexican or American foods
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Oct 11, 2026, 6:59 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Human Models of Selective Insulin Resistance: Alpelisib, Part I

NCT06354088
View directory record Official record
Conditions
Insulin Resistance, Prediabetic State, Overweight and Obesity, Non-Alcoholic Fatty Liver Disease
Interventions
Alpelisib 300 mg, Placebo, [1-13C] sodium acetate, [6,6-2H2] D-glucose, Mixed Meal Tolerance Test, Nestlé BOOST Plus
Drug · Diagnostic Test · Dietary Supplement
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 11, 2026, 6:59 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Primary Intervention With Mucosal Insulin

NCT02620553
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Human Insulin, Oral Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
2 Years to 7 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 11, 2026, 6:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Glycemic Load & Resistance Training on Endothelial Function & Insulin Sensitivity

NCT01755962
View directory record Official record
Conditions
160 Participants Aged 18-35 Years and Obese (BMI ≥30) Open to Men and Women of All Ethnicity
Interventions
Glycemic Load, Resistance Training
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 35 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 11, 2026, 6:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Exercise and Insulin Signaling in Human Skeletal Muscle

NCT02987491
View directory record Official record
Conditions
Insulin Sensitivity, Obesity, Sedentary Lifestyle
Interventions
Exercise
Behavioral
Lead sponsor
Oregon State University
Other
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Corvallis, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 11, 2026, 6:59 PM EDT
Terminated Phase 2 Interventional Results available

A Study of R1507 in Participants With Recurrent or Refractory Sarcoma

NCT00642941
View directory record Official record
Conditions
Sarcoma
Interventions
RG1507
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
22
States / cities
Duarte, California • Los Angeles, California • Santa Monica, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 11, 2026, 6:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)

NCT01275131
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin aspart, Recombinant human hyaluronidase PH20 (rHuPH20)
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 11, 2026, 6:59 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Epigenetic Regulation of Human Adipose Tissue Distribution

NCT02728635
View directory record Official record
Conditions
Obesity
Interventions
Dual-energy X-ray absorptiometry (DEXA)/ Magnetic resonance imaging (MRI) and Magnetic resonance spectroscopy (MRS), Adipose tissue biopsies, FSIGTT/ RMR
Other · Procedure
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 11, 2026, 6:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell Function

NCT00949663
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Placebo, Glucose-dependent Insulinotropic Polypeptide (GIP), Xenin-25, Glucose-dependent Insulinotropic Polypeptide plus Xenin-25
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 22, 2014 · Synced Oct 11, 2026, 6:59 PM EDT
Terminated Phase 3 Interventional

Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes

NCT00411892
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
pioglitazone, inhaled human insulin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
110
States / cities
Ozark, Alabama • Tuscaloosa, Alabama • Vestavia Hills, Alabama + 100 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 11, 2026, 6:59 PM EDT
Terminated Phase 3 Interventional Results available

Effect of Weight and Insulin Sensitivity on Reproductive Function in PCOS

NCT01482286
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin, Dietary Restriction, Exercise Training
Drug · Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 11, 2026, 6:59 PM EDT